Literature DB >> 19933862

Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani.

Ankur Sharma1, Rentala Madhubala.   

Abstract

Resistance of Leishmania donovani to sodium antimony gluconate has become a critical issue in the current, prolonged epidemic in India. Hence, there is an urgent need for a vaccine that is protective against both antimony-susceptible and -resistant strains of L. donovani. The multigene LD1 locus located on chromosome 35 of Leishmania is amplified in approximately 15% of the isolates examined. The open reading frame F (ORFF), a potential vaccine candidate against visceral leishmaniasis, is part of the multigene LD1 locus. ORFF was expressed as a chimeric conjugate of ubiquitin to elicit an Ag-specific cell-mediated immune response. Analysis of the cellular immune responses of ubiquitin-conjugated ORFF (UBQ-ORFF) DNA-immunized, uninfected BALB/c mice demonstrated that the vaccine induced enhanced IFN-gamma-producing CD4(+) and CD8(+) T cells compared with nonubiquitinated ORFF DNA vaccine. Higher levels of IL-12 and IFN-gamma and the low levels of IL-4 and IL-10 further indicated that the immune responses with UBQ-ORFF were mediated toward the Th1 rather than Th2 type. Infection of immunized mice with either the antimony-susceptible (AG83) or -resistant (GE1F8R) L. donovani strain showed that UBQ-ORFF DNA vaccine induced higher protection when compared with ORFF DNA. UBQ-ORFF DNA-immunized and -infected mice showed a significant increase in IL-12 and IFN-gamma and significant down-regulation of IL-10. High levels of production of nitrite and superoxide, two macrophage-derived oxidants that are critical in controlling Leishmania infection, were observed in protected mice. The feasibility of using ubiquitinated-conjugated ORFF DNA vaccine as a promising immune enhancer for vaccination against both antimony-susceptible and -resistant strains of L. donovani is reported.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19933862     DOI: 10.4049/jimmunol.0900132

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Proteomic-based approach to gain insight into reprogramming of THP-1 cells exposed to Leishmania donovani over an early temporal window.

Authors:  Alok Kumar Singh; Rajeev Kumar Pandey; Jair Lage Siqueira-Neto; Yong-Jun Kwon; Lucio H Freitas-Junior; Chandrima Shaha; Rentala Madhubala
Journal:  Infect Immun       Date:  2015-02-17       Impact factor: 3.441

2.  The lignan niranthin poisons Leishmania donovani topoisomerase IB and favours a Th1 immune response in mice.

Authors:  Sayan Chowdhury; Tulika Mukherjee; Rupkatha Mukhopadhyay; Budhaditya Mukherjee; Souvik Sengupta; Sharmila Chattopadhyay; Parasuraman Jaisankar; Syamal Roy; Hemanta K Majumder
Journal:  EMBO Mol Med       Date:  2012-10       Impact factor: 12.137

3.  Ubiquitin conjugation of hepatitis B virus core antigen DNA vaccine leads to enhanced cell-mediated immune response in BALB/c mice.

Authors:  Jian-Hua Chen; Yong-Sheng Yu; Hong-Hong Liu; Xiao-Hua Chen; Min Xi; Guo-Qing Zang; Zheng-Hao Tang
Journal:  Hepat Mon       Date:  2011-08       Impact factor: 0.660

4.  Vaccine Development Against Leishmania donovani.

Authors:  Amrita Das; Nahid Ali
Journal:  Front Immunol       Date:  2012-05-15       Impact factor: 7.561

Review 5.  Vaccines to prevent leishmaniasis.

Authors:  Rajiv Kumar; Christian Engwerda
Journal:  Clin Transl Immunology       Date:  2014-03-14

6.  Activity of a novel sulfonamide compound 2-nitro-N-(pyridin-2-ylmethyl)benzenesulfonamide against Leishmania donovani.

Authors:  Manas R Dikhit; Bidyut Purkait; Ruby Singh; Bikash Ranjan Sahoo; Ashish Kumar; Rajiv K Kar; Md Yousuf Ansari; Savita Saini; Kumar Abhishek; Ganesh C Sahoo; Sushmita Das; Pradeep Das
Journal:  Drug Des Devel Ther       Date:  2016-05-26       Impact factor: 4.162

Review 7.  Possibilities and challenges for developing a successful vaccine for leishmaniasis.

Authors:  Saumya Srivastava; Prem Shankar; Jyotsna Mishra; Sarman Singh
Journal:  Parasit Vectors       Date:  2016-05-12       Impact factor: 3.876

8.  Leishmania eukaryotic initiation factor (LeIF) inhibits parasite growth in murine macrophages.

Authors:  Olga Koutsoni; Mourad Barhoumi; Ikram Guizani; Eleni Dotsika
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

Review 9.  Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches.

Authors:  Sumit Joshi; Keerti Rawat; Narendra Kumar Yadav; Vikash Kumar; Mohammad Imran Siddiqi; Anuradha Dube
Journal:  Front Immunol       Date:  2014-08-22       Impact factor: 7.561

Review 10.  Post-Genomics and Vaccine Improvement for Leishmania.

Authors:  Negar Seyed; Tahereh Taheri; Sima Rafati
Journal:  Front Microbiol       Date:  2016-04-06       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.